• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Ab­b­Vie’s im­munol­o­gy block­busters make up for Hu­mi­ra sales drop in Q3

7 months ago
Pharma

At­las of tu­mors re­veals in 3D how cells change in­to can­cer

7 months ago
R&D
Discovery

Hints of im­pa­tience grow with Bio­gen as it tries to find a bridge to growth

7 months ago
R&D
Pharma

FDA says all ver­sions of Novo's GLP-1 weight loss drugs are now avail­able

7 months ago
FDA+

As­traZeneca Chi­na ex­ec probed by lo­cal au­thor­i­ties

7 months ago
China
Law

GSK cuts 24-va­lent pneu­mo­coc­cal pro­gram for adults due to com­pe­ti­tion

7 months ago
R&D

Leal Ther­a­peu­tics rais­es $45M; Syn­Ox adds to Se­ries B

7 months ago
News Briefing

Lund­beck dou­bled its of­fer for Long­board over six months, new fil­ing shows

7 months ago
Deals

Blue Earth Ther­a­peu­tics snags $76M for both al­pha and be­ta ra­dio­ther­a­pies

7 months ago
Financing
Startups

Bio­gen signs mol­e­c­u­lar glue deal, rais­es year­ly pro­jec­tions

7 months ago
Deals
R&D

Up­dat­ed: Lil­ly’s shares tank af­ter trim­ming rev­enue guid­ance. It al­so cut three as­sets

7 months ago
Pharma

A start­up backed by No­bel win­ner David Bak­er takes an AI twist on an­ti­bod­ies

7 months ago
Financing
Startups

GSK re­mains ‘very con­fi­dent’ in RSV vac­cine amid com­pe­ti­tion, sales slump

7 months ago
Pharma

Ax­o­nis snags $115M to test oral drugs for epilep­sy and neu­ro­path­ic pain

7 months ago
Financing
Startups

Sage, Bio­gen won't pur­sue ma­jor de­pres­sion ap­proval for post­par­tum pill

7 months ago
R&D

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

7 months ago
R&D
Pharma

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

7 months ago
FDA+
Manufacturing

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

7 months ago
Pharma
FDA+

Lex­i­con's once-re­ject­ed di­a­betes drug is ques­tioned again by FDA ahead of ad­comm

7 months ago
Pharma
FDA+

Coya shares sink on Phase 2 Alzheimer's da­ta for de­pri­or­i­tized drug

7 months ago
R&D

No­var­tis ex­pands Scem­blix la­bel to first-line CML pa­tients

7 months ago
Pharma
FDA+

Sh­iono­gi touts topline da­ta for Covid-19 an­tivi­ral for post-ex­po­sure treat­ment

7 months ago
R&D
Pharma

Mil­li­pore­Sig­ma in­vests €70M to triple ADC man­u­fac­tur­ing at US site 

7 months ago
Manufacturing

PacBio bets on 'in­flec­tion point' with $500 long-read genome

7 months ago
R&D
Diagnostics
First page Previous page 83848586878889 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times